Difference between revisions of "Elotuzumab (Empliciti)"
Jump to navigation
Jump to search
m (Jwarner moved page Elotuzumab (HuLuc63) to Elotuzumab (Empliciti): FDA approval) |
m |
||
| Line 12: | Line 12: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Multiple myeloma]] | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
No information available. | No information available. | ||
| Line 44: | Line 20: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 5/19/2014: Granted FDA [http://www.fda.gov/ForPatients/Approvals/Fast/ucm405397.htm Breakthrough Therapy designation] "for use in combination with [[Lenalidomide (Revlimid) | lenalidomide]] and [[Dexamethasone (Decadron) | dexamethasone]] for the treatment of [[Multiple myeloma | multiple myeloma]] in patients who have received one or more prior therapies." | * 5/19/2014: Granted FDA [http://www.fda.gov/ForPatients/Approvals/Fast/ucm405397.htm Breakthrough Therapy designation] "for use in combination with [[Lenalidomide (Revlimid) | lenalidomide]] and [[Dexamethasone (Decadron) | dexamethasone]] for the treatment of [[Multiple myeloma | multiple myeloma]] in patients who have received one or more prior therapies." | ||
| + | * 11/30/2015: FDA approved "in combination with [[Lenalidomide (Revlimid) | lenalidomide]] and [[Dexamethasone (Decadron) | dexamethasone] for the treatment of patients with [[Multiple myeloma | multiple myeloma]] who have received one to three prior therapies." | ||
| + | ==Also known as== | ||
| + | HuLuc63 | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| Line 57: | Line 36: | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
| − | [[Category: | + | [[Category:Drugs FDA approved in 2015]] |
Revision as of 02:01, 1 December 2015
0 regimens on this page
0 variants on this page
|
General information
Class/mechanism from NCI Drug Dictionary: A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Diseases for which it is used
Patient drug information
No information available.
History of changes in FDA indication
- 5/19/2014: Granted FDA Breakthrough Therapy designation "for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies."
- 11/30/2015: FDA approved "in combination with lenalidomide and [[Dexamethasone (Decadron) | dexamethasone] for the treatment of patients with multiple myeloma who have received one to three prior therapies."
Also known as
HuLuc63